Category Archives: Immunology

‘I Am a Scientist Working With Severe Cases of COVID-19’ – Newsweek

Before the pandemic, I was studying immunology in the field of virus infections. I am a professor of immunobiology and molecular, cellular and developmental biology at Yale School of Medicine, and an investigator of the Howard Hughes Medical Institute. With my team at Yale's Iwasaki lab, we had been studying how the immune system detects viruses and how innate and adaptive immune systems are connected. Based on these insights, we are designing better vaccines.

We had been studying viruses including herpes, influenza and Zika for years, so when SARS-CoV-2 (COVID-19) hit we were prepared to tackle the questions it provoked. At the end of February, we started pivoting our work to focus on COVID-19. Our first effort was mostly focused on testing, because in the early stages of the virus there was no real testing capacity in the U.S.

With a number of collaborators, we helped set up a polymerase chain reaction (PCR) based testing strategy, and carried out numerous PCR testing in the lab to help identify COVID-19 infected patients and healthcare workers.

In parallel, my lab quickly moved into studying immunology, which is our specialty.

Newsweek subscription offers >

Read more

Now, in September in Connecticut, there are very few COVID-19 cases. But back in March and April we were seeing cases spiking in the state. So, we had this unique opportunity to start enrolling patients at Yale New Haven Hospital, which was seeing many cases of COVID-19, as part of our Yale IMPACT (Implementing Medical and Public Health Action Against Coronavirus CT) study. We were able to do white blood cell analysis on 113 patients to study and follow them over time to understand the changes in their immune responses in real time, and that work has resulted in a study that was published in Nature.

Our aim was to study the immune response in different people; those who were having a moderate case of COVID-19 and are recovering from the infection, and those who were having a severe response to the COVID-19 virus, some of whom unfortunately did pass away from this disease.

Every four days or so, we would take their nasopharyngeal swabs (samples of secretions from the nose and throat) and blood and analyse what was happening, and that led to very interesting insights. Firstly, with the virus load that we measure from the patients' nose, we observed the severe and moderate patients started off with similar levels. But then, though the moderate patients were able to clear the virus eventually, the severe patients never really could.

Newsweek subscription offers >

So the first thing we noticed was that one of the elements that distinguished between moderate and severe cases of the disease was the inability to control the virus in the severe case. The second thing we learned when we collected patients' plasma and observed their cytokines.

Cytokines are small proteins important in cell signalling because they transmit information from one cell to another.

The COVID-19 viral load in severe patients was associated with increased levels of these proteins. They can have a positive or a negative effect on the body's immune response to a disease, depending on the information they are transmitting between cells.

It turns out that there are a number of distinct features that are associated with the COVID-19 patients we observed and that interestingly correlate with their recovery from this disease. I was really floored when I saw these features, because there were some unusual things that we had not anticipated seeing.

Essentially, we saw that patients who eventually recovered had proteins (growth factors) in their blood that were encouraging their cells to repair. Growth factors can repair the damaged tissue in blood vessels and lung cells that happens during viral infection. In contrast, the patients who went on to have really severe cases of COVID-19 had proteins in their blood that were misfiring in all sorts of strange ways, and in some cases, reacting as if there was a parasite in the body!

It's pretty unusual during a viral infection to have anti-parasite responses going offbut many of the very severe patients we monitored exhibited these.

Compared to other viruses we have been studying over the years, we had never seen this kind of anti-parasite response coming up. So, it's likely that this virus is doing something to the host that is disorienting them in some way that allows this type of misfiring to occur. We don't know what that is yet, it may be intrinsic to the virus or it may be somehow the host is being triggered by some features of this virus that is elevating all kinds of these cytokine proteins. It may even be a body's way of trying to recover from infection.

When the patients were clustered based on their cytokine levels, they separated out into three clusters. We observed that patients who recovered didn't have much in the way of these misfiring proteins, but the second cluster of severe cases and the third cluster of very severe cases both did, and the third cluster had very rapid decline with the disease. That third cluster included patients who had the greatest numbers of misfiring proteins.

When I first saw these unusual signatures, I thought there was some technical glitch. So I asked the scientists to make sure they repeated this analysis multiple times, and these signatures kept coming up. But then during the course of study we started seeing other pre-prints, scientific papers that have not yet been peer-reviewed, that were reporting these anti-parasite responses also. So we knew we weren't alone in seeing this, and now we have seen several studies that confirm this.

One of the things that we reported is that even during the first 12 days of COVID-19 symptom onset there are certain proteins mentioned above that correlate with worse COVID-19 disease outcome. So, by measuring these early, we can inform clinicians that a patient, if they exhibit such cytokine proteins, is someone to pay attention to versus others who may look just as sick but aren't exhibiting in the same way.

In addition, we found bio-markers that we can use to look at patients to help predict what might happen. It's very useful to have this information because you can prepare Intensive Care Unit (ICU) beds in anticipation, as well as to potentially give these patients more suitable treatment.

Way before our COVID-19 study came out I had been tweeting about targeting inflammasomes because we have seen evidence of that activation in multiple papers. Inflammasomes are one type of inflammation that happens during a severe infection.

As the name suggests, inflammasomes are a very toxic form of inflammation. It is a large protein complex that forms inside the cell in response to bacterial and viral infection. Inflammasomes can transform cytokine proteins such as IL-1b and IL-18 into active forms. It can also cause "fiery death" of cells, which is known as pyroptosis. We found clear signatures of inflammasome activation that correlated with worse disease and death from COVID-19.

My lab had the knowledge and tools to react before COVID-19 hit, and it is an amazing privilege to be able to work on a pandemic to try and help people. We feel very energized because we are helping people and there are tangibles that come out of this type of research. Things are happening in real time; people are reaching out to me with different ideas for clinical trials based on what we have found. It's really exciting that a study result can trigger clinical trials in a very rapid manner, and be able to predict what might happen using a mouse model we developed to mimic COVID-19.

I feel honored to be working in this area. The pandemic has given me an opportunity to communicate science because more people are now interested. This real interest in immunology and vaccines is also an opportunity for me to educate the public about the immune system. Immunology is becoming extremely important now that public health measures have failed in many countries. Now, we really need the immune system to be able to kick in with the right vaccines to protect us.

I hope that our insights will help people cope with this infection better and eventually, recover. We continue to investigate this virus and have recently released research into whether immune responses to COVID-19 differ between the sexes.

To help just even one person survive this virus would be the most gratifying thing a scientist could hope for.

Professor Akiko Iwasaki focuses on the mechanisms of immune defense against viruses at mucosal surfaces, which are a major site of entry for infectious agents. She is a professor of immunobiology and molecular, cellular and developmental biology at Yale School of Medicine, and an investigator of the Howard Hughes Medical Institute. Professor Iwasaki has received numerous awards and honors for her work and is also well known for her Twitter advocacy on women and underrepresented minorities in the science and medicine fields. You can follow her on Twitter @VirusesImmunity

All views expressed in this piece are the writer's own.

As told to Jenny Haward.

Read the original:
'I Am a Scientist Working With Severe Cases of COVID-19' - Newsweek

Worldwide Human Microbiome Immunology Therapeutics Industry to 2025 – The US Dominates the Global Market Landscape – PRNewswire

DUBLIN, Sept. 3, 2020 /PRNewswire/ -- The "Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" clinical trials has been added to ResearchAndMarkets.com's offering.

The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology. The relevance that it has shown for the welfare of the society and pharmaceutical industry has led to the development of a transdisciplinary environment that is however conducive to innovation with a mission to abolish the limitations in the pharmaceutical industry through excellence in microbiome research, awareness and outreach. Over the years now, gut microbiome is estimated to implicate success for the various immunotherapies.

Microbiome's role in immunology practices is to transform world-class treatment into the medicine of today and tomorrow. It is highly recognizable that the healthcare issues that mankind is facing today is now bigger than any one solution. The treatment of certain diseases requires multiple options for the treatment and ultimately prevention. Therefore, the amalgamation of two different treatment paradigms i.e. microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time. The ways in which microbiome is understood and manipulated to serve the immunological aspects has given great interest to all the researchers.

The essential and usual concept of immunology depicts targeting the immune system of the body to provoke an immune response with huge impact but then the unsuccessful implication of immunology therapies driven treatments led to an exploration of several other basic concepts that could play an important role in boosting the immune system when combined. Looking forward, the microbiome community in the gut represented beneficial patterns with respect to further research. The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.

All over the world, the amalgamation of the two has been well accepted and appreciated by the patients, physicians and the clinicians. Investigation of all the working sides of microbiome and how it plays an important role in boosting the manipulated immune cells have recently started in large numbers as the technology available in the medical field allows to capture it accurately. To facilitate the microbiome and immunology community in order to extract the best and trending opportunities that are stemmed into the microbiome research, the experts from both the relevant disciplines are analyzing it through clinical researches and surveys. Further, the area is getting supported by 86 different clinical trials getting conducted in different countries.

The Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025 report summarizes the view of the wider opportunities that are associated microbiome community for the advancement of the scientific information regarding immunology. The science that is related to microbiome has high interdisciplinary and various opportunities that somehow have remained hidden in the medical world. It is believed that the opportunities and all the desirable tangible benefits microbiome is capable of delivering when combined with immunology is large and needs coordinated and constructive approach. The call to the two different sectors i.e. microbiology and immunology is estimated to unlock the potential and promising benefits of microbiome. The approach leading to the extraction of advantages if properly embedded in the microbiome and immunology research, the future benefits will be huge

Report Highlights:

Key Topics Covered:

1. Overview of Microbiome1.1 Introduction to Microbiome1.2 History & Evolution of Microbiome

2. Role of Microbiome in Human Body

3. Microbiome: Various Forms3.1 Gut Microbiome3.2 Lung Microbiome3.3 Skin Microbiome3.4 Microbiome in Other Parts of the Body

4. Mechanism of Microbiome Activity4.1 Nature of Immune Response4.1.1 Immunosuppressive Activity4.1.2 Immunostimulatory Activity4.2 Messengers Involves in Microbiome Mechanism4.2.1 MAMPs/PAMPs4.2.2 Microbial Metabolites As Messengers4.2.3 Host Cytokines As Messengers4.2.4 Immune Cells As Messengers

5. Technological Requirement for Microbiota5.1 Technologies Used5.1.1 iChip5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME)5.1.3 Gut-on-a-Chip System5.1.4 Colonic Stem Cell Construction5.2 Harnessing & Engineering the Microbiome5.2.1 Additive Approaches5.2.2 Subtractive Approaches

6. Need for Microbiome Immunology

7. Therapeutic Applications of Microbiome Immunology7.1 Microbiome Therapy7.2 Precision Medicine7.3 Drug discovery7.4 Biomarkers & Therapy Optimization

8. Human Microbiota in Infectious Diseases8.1 Infection with Clostridium Difficile8.2 Infection with Helicobacter Pylori8.3 Bacterial Vaginosis8.4 Infection with HIV

9. The Human Microbiota & Liver Diseases9.1 Non-Alcoholic Fatty Liver Disease (NAFLD)9.2 Alcoholic Liver Diseases (ALD)9.3 Liver Fibrosis & Cirrhosis

10. The Human Microbiota & Metabolic Disorders10.1 Obesity10.2 Type 2 Diabetes

11. The Human Microbiota & Other Diseases11.1 Microbiota & Allergic Diseases11.2 Microbiota & Psychiatric Diseases

12. Microbiome in Immuno Oncology12.1 Role of Microbiome in Immuno Oncology12.2 Microbiome Mechanism in Oncogenesis & Tumor Suppression

13. Microbiome Application by Cancer Types13.1 Gastric Cancer13.2 Colorectal Cancer13.3 Esophageal Cancer13.4 Hepatocellular Carcinoma13.5 Melanoma13.6 Solid Tumors

14. Industrial Approaches of Microbiome Therapy in Oncology14.1 Bacterial Approaches14.1.1 Fecal Microbiota Transplantation (FMT)14.1.2 Synthetic Bacteria14.1.3 Microbial Culture14.2 Microbiome as Vaccine14.3 Microbiome as Small Molecules14.4 Microbiome Therapy using Phage Virus

15. Global Human Microbiome Market Analysis15.1 Overview15.2 Human Microbiome Market Segmentation15.2.1 Regional Segmentation15.2.2 Disease Based Segmentation15.2.3 Segmentation by Application

16. Clinical Pipeline of Microbiome Based Therapy16.1 Microbiome Modulators in Clinical Trial16.2 Cancer Related Clinical Trials16.2.1 Preclinical & Discovery Phase16.2.2 Active Clinical Trials16.3 Clinical Trial Related To FMT16.3.1 Clinical Trial for Recurrent C. difficile16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD)16.3.3 Other FMT Related Clinical Trials

17. Global Microbiome Modulators Clinical Pipeline By Company, Indication & Phase17.1 Research17.2 Preclinical17.3 Clinical17.4 Phase-I17.5 Phase-I/II17.6 Phase-II17.7 Phase-II/III17.8 Phase-III

18. Marketed Microbiome Modulators Clinical Insight18.1 Sodium Oligomannurarate - Shanghai Green Valley Pharmaceutical18.2 Miya-BM

19. Global Microbiome Immunology Therapeutics Market Growth Drivers

20. Microbiome Technology - Investments, Acquisitions & Collaborations by Leading Microbiome Companies

21. Blockades in the Microbiome Immunology Market21.1 Stable Engraftment21.2 Development of Clinically Relevant Sensors21.3 Robustness and Evolutionary Stability of Genetic Circuits21.4 Regulation, Safety and Biocontainment

22. Global Microbiome Immunology Market Future Panorama

23. Competitive Landscape23.1 4D Pharma23.2 AbbVie23.3 AstraZeneca plc23.4 Biocodex23.5 Bristol Mayer Squibb23.6 Corebiome/Diversigen23.7 Elogi Bioscience23.8 Enterome23.9 Ferring Pharmaceuticals23.10 Finch Therapeutics23.11 Maat Pharma23.12 Merck23.13 Microbiome Therapeutics23.14 Novartis23.15 OpenBiome23.16 Pfizer23.17 Rebiotix23.18 Second Genome23.19 Seres Therapeutics23.20 Symberix23.21 Takeda Pharmaceuticals23.22 Vedanta Bioscience

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/u5kzzz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Go here to see the original:
Worldwide Human Microbiome Immunology Therapeutics Industry to 2025 - The US Dominates the Global Market Landscape - PRNewswire

Insights on the Human Microbiome Immunology Therapeutics Global Market to 2025 – Featuring Finch Therapeutics, MaaT Pharma & Merck Among Others -…

Dublin, Sept. 02, 2020 (GLOBE NEWSWIRE) -- The "Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" clinical trials has been added to ResearchAndMarkets.com's offering.

The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology. The relevance that it has shown for the welfare of the society and pharmaceutical industry has led to the development of a transdisciplinary environment that is however conducive to innovation with a mission to abolish the limitations in the pharmaceutical industry through excellence in microbiome research, awareness and outreach. Over the years now, gut microbiome is estimated to implicate success for the various immunotherapies.

Microbiome's role in immunology practices is to transform world-class treatment into the medicine of today and tomorrow. It is highly recognizable that the healthcare issues that mankind is facing today is now bigger than any one solution. The treatment of certain diseases requires multiple options for the treatment and ultimately prevention. Therefore, the amalgamation of two different treatment paradigms i.e. microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time. The ways in which microbiome is understood and manipulated to serve the immunological aspects has given great interest to all the researchers.

The essential and usual concept of immunology depicts targeting the immune system of the body to provoke an immune response with huge impact but then the unsuccessful implication of immunology therapies driven treatments led to an exploration of several other basic concepts that could play an important role in boosting the immune system when combined. Looking forward, the microbiome community in the gut represented beneficial patterns with respect to further research. The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.

All over the world, the amalgamation of the two has been well accepted and appreciated by the patients, physicians and the clinicians. Investigation of all the working sides of microbiome and how it plays an important role in boosting the manipulated immune cells have recently started in large numbers as the technology available in the medical field allows to capture it accurately. To facilitate the microbiome and immunology community in order to extract the best and trending opportunities that are stemmed into the microbiome research, the experts from both the relevant disciplines are analyzing it through clinical researches and surveys. Further, the area is getting supported by 86 different clinical trials getting conducted in different countries.

The Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025 report summarizes the view of the wider opportunities that are associated microbiome community for the advancement of the scientific information regarding immunology. The science that is related to microbiome has high interdisciplinary and various opportunities that somehow have remained hidden in the medical world. It is believed that the opportunities and all the desirable tangible benefits microbiome is capable of delivering when combined with immunology is large and needs coordinated and constructive approach. The call to the two different sectors i.e. microbiology and immunology is estimated to unlock the potential and promising benefits of microbiome. The approach leading to the extraction of advantages if properly embedded in the microbiome and immunology research, the future benefits will be huge

Report Highlights:

Key Topics Covered:

1. Overview of Microbiome1.1 Introduction to Microbiome1.2 History & Evolution of Microbiome

2. Role of Microbiome in Human Body

3. Microbiome: Various Forms3.1 Gut Microbiome3.2 Lung Microbiome3.3 Skin Microbiome3.4 Microbiome in Other Parts of the Body

4. Mechanism of Microbiome Activity4.1 Nature of Immune Response4.1.1 Immunosuppressive Activity4.1.2 Immunostimulatory Activity4.2 Messengers Involves in Microbiome Mechanism4.2.1 MAMPs/PAMPs4.2.2 Microbial Metabolites As Messengers4.2.3 Host Cytokines As Messengers4.2.4 Immune Cells As Messengers

5. Technological Requirement for Microbiota5.1 Technologies Used5.1.1 iChip5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME)5.1.3 Gut-on-a-Chip System5.1.4 Colonic Stem Cell Construction5.2 Harnessing & Engineering the Microbiome5.2.1 Additive Approaches5.2.2 Subtractive Approaches

6. Need for Microbiome Immunology

7. Therapeutic Applications of Microbiome Immunology7.1 Microbiome Therapy7.2 Precision Medicine7.3 Drug discovery7.4 Biomarkers & Therapy Optimization

8. Human Microbiota in Infectious Diseases8.1 Infection with Clostridium Difficile8.2 Infection with Helicobacter Pylori8.3 Bacterial Vaginosis8.4 Infection with HIV

9. The Human Microbiota & Liver Diseases9.1 Non-Alcoholic Fatty Liver Disease (NAFLD)9.2 Alcoholic Liver Diseases (ALD)9.3 Liver Fibrosis & Cirrhosis

10. The Human Microbiota & Metabolic Disorders10.1 Obesity10.2 Type 2 Diabetes

11. The Human Microbiota & Other Diseases11.1 Microbiota & Allergic Diseases11.2 Microbiota & Psychiatric Diseases

12. Microbiome in Immuno Oncology12.1 Role of Microbiome in Immuno Oncology12.2 Microbiome Mechanism in Oncogenesis & Tumor Suppression

13. Microbiome Application by Cancer Types13.1 Gastric Cancer13.2 Colorectal Cancer13.3 Esophageal Cancer13.4 Hepatocellular Carcinoma13.5 Melanoma13.6 Solid Tumors

14. Industrial Approaches of Microbiome Therapy in Oncology14.1 Bacterial Approaches14.1.1 Fecal Microbiota Transplantation (FMT)14.1.2 Synthetic Bacteria14.1.3 Microbial Culture14.2 Microbiome as Vaccine14.3 Microbiome as Small Molecules14.4 Microbiome Therapy using Phage Virus

15. Global Human Microbiome Market Analysis15.1 Overview15.2 Human Microbiome Market Segmentation15.2.1 Regional Segmentation15.2.2 Disease Based Segmentation15.2.3 Segmentation by Application

16. Clinical Pipeline of Microbiome Based Therapy16.1 Microbiome Modulators in Clinical Trial16.2 Cancer Related Clinical Trials16.2.1 Preclinical & Discovery Phase16.2.2 Active Clinical Trials16.3 Clinical Trial Related To FMT16.3.1 Clinical Trial for Recurrent C. difficile16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD)16.3.3 Other FMT Related Clinical Trials

17. Global Microbiome Modulators Clinical Pipeline By Company, Indication & Phase17.1 Research17.2 Preclinical17.3 Clinical17.4 Phase-I17.5 Phase-I/II17.6 Phase-II17.7 Phase-II/III17.8 Phase-III

18. Marketed Microbiome Modulators Clinical Insight18.1 Sodium Oligomannurarate - Shanghai Green Valley Pharmaceutical18.2 Miya-BM

19. Global Microbiome Immunology Therapeutics Market Growth Drivers

20. Microbiome Technology - Investments, Acquisitions & Collaborations by Leading Microbiome Companies

21. Blockades in the Microbiome Immunology Market21.1 Stable Engraftment21.2 Development of Clinically Relevant Sensors21.3 Robustness and Evolutionary Stability of Genetic Circuits21.4 Regulation, Safety and Biocontainment

22. Global Microbiome Immunology Market Future Panorama

23. Competitive Landscape23.1 4D Pharma23.2 AbbVie23.3 AstraZeneca plc23.4 Biocodex23.5 Bristol Mayer Squibb23.6 Corebiome/Diversigen23.7 Elogi Bioscience23.8 Enterome23.9 Ferring Pharmaceuticals23.10 Finch Therapeutics23.11 Maat Pharma23.12 Merck23.13 Microbiome Therapeutics23.14 Novartis23.15 OpenBiome23.16 Pfizer23.17 Rebiotix23.18 Second Genome23.19 Seres Therapeutics23.20 Symberix23.21 Takeda Pharmaceuticals23.22 Vedanta Bioscience

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/d6z6gb

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See original here:
Insights on the Human Microbiome Immunology Therapeutics Global Market to 2025 - Featuring Finch Therapeutics, MaaT Pharma & Merck Among Others -...

Immunologists Receive Multi-Million Funding Boost to Research Role of Immune System in COVID-19 – HospiMedica

Immunologists from The University of Edinburgh (Edinburgh, Scotland) have received a multimillion pound funding boost to research the role of the immune system in COVID-19.

The funding comes from the UK Coronavirus Immunology Consortium (UK-CIC), a major initiative set-up to tackle the COVID-19 pandemic. The GBP 8.4 million Consortium launched by UK Research and Innovation and the National Institute for Health Research brings together 17 UK research institutes to investigate vital aspects of disease immunity, including why the disease affects some people worse than others.

Dr. Kenneth Baillie, from the Roslin Institute, will work with collaborators to analyze immunity data in people hospitalized because of COVID-19 symptoms. Professor Sarah Walmsley from the Centre for Inflammation Research will research the role of immune systems in determining susceptibility to the virus and how it varies as people age. A third study led by Dr. Christopher Lucas from the Centre for Inflammation Research will investigate the key features of fatal COVID-19 cases and the impact the virus has on lungs and other vital organs. UK-CIC will use resources from ongoing UK studies, including ISARIC-4C, which is following more than 75,000 people hospitalized with COVID-19, and GenOMICC, a study to sequence the genomes of people with the disease, led by Dr. Kenneth Baillie.

We have learned so much from COVID-19 patients during the past six months. However, there is only so much that we can learn from clinical examinations and blood tests, said Dr. Christopher Lucas. By having a deeper look at those who have died from COVID-19 through post-mortem examination, we will increase our understanding of what is happening to the body in the most severe cases of this disease. Critically, this will allow us to rapidly answer key clinical questions and help inform the care of patients and the development of new treatments.

Related Links:The University of Edinburgh

The rest is here:
Immunologists Receive Multi-Million Funding Boost to Research Role of Immune System in COVID-19 - HospiMedica

UK government to invest 8.4 million into COVID-19 immunology research – Drug Target Review

The UK government will invest 8.4 million in COVID-19 research projects to reveal more information that can be used to develop therapies and vaccines against the disease.

The UK government has announced it is investing 8.4 million in COVID-19 immunology research projects across the UK, including at the Universities of Edinburgh, Glasgow and Dundee. According to the government, this is the biggest ever contribution to COVID-19 immunology research in the UK.

Three new UK-wide studies will receive funding from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR) to understand immune responses to COVID-19.It is hoped these studies will improve the treatment of patients and inform the development of vaccines and therapies.

The Scottish universities are taking part in the largest study, the UK Coronavirus Immunology Consortium, which will receive 6.5 million and bring together leading immunologists from 17 UK universities. The University of Edinburgh is also involved in another study.

Dr Christopher Lucas at the University of Edinburgh, will lead a study on the key features of fatal COVID-19 and the impact the virus has upon the lungs and other vital organs. Using authorised hospital post-mortem examinations of patients who have died from COVID-19, this study will provide a unique opportunity for expert clinicians and scientists to study the whole body in a level of detail that is not possible during life.

We have learned so much from COVID-19 patients during the past six months. However, there is only so much that we can learn from clinical examinations and blood tests.By having a deeper look at those who have died from COVID-19 through post-mortem examination, we will increase our understanding of what is happening to the body in the most severe cases of this disease.Critically, this will allow us to rapidly answer key clinical questions and help inform the care of patients and the development of new treatments, Dr Lucas said.

The UK Coronavirus Immunology Consortium will investigate key questions including how long immunity from COVID-19 lasts andwhy some patients immune systems are better able to fight off the virus.

According to the researchers, better understanding of these immune responses, particularly the T-cell response, could provide targets for new therapies to treat COVID-19 and inform the efforts to develop a vaccine.

The project will use samples and data from major UK COVID-19 projects already underway, funded by UKRI and NIHR.

Professor Massimo Palmarini, Director of the Medical Research Council-University of Glasgow Centre for Virus Research (CVR) said: My colleagues and I at the CVR are extremely proud to be involved in the UK-CIC consortium and are grateful to UKRI and NIHR for the generous funding support. It is now more important than ever that the immunology community work together, as we aim to address important, unanswered questions about SARS-CoV-2 as we move through this pandemic.

Read the original post:
UK government to invest 8.4 million into COVID-19 immunology research - Drug Target Review

Trinity is at the Heart of Immunology. It Needs to Take a Lead on Testing – The University Times

" );jQuery( ".stuck" ).fadeIn( 300 );}},{offset: '0%',});if ($(window).width() -1 || ref1.indexOf(twitter) > -1 || ref1.indexOf(tco) > -1 ) {jQuery('.utpost-content').readmore({ speed: 75, moreLink: '', lessLink: '', collapsedHeight: 375, embedCSS: false, heightMargin: 100, });} else { }}});}); jQuery(window).resize(function() {console.log(jQuery(window).width());if (jQuery(window).width() > 584) { jQuery('.utpost-content').readmore('destroy'); }else{ }});jQuery(window).trigger('resize');

In an interview with The University Times earlier this week, Trinity immunologist Luke ONeill advised that College test all staff and students for the coronavirus twice weekly. A familiar and reassuring voice throughout the pandemic, ONeill asserted that frequent testing was the best way to minimise the chances of outbreaks on campus.

Of course, it is not exactly new information that frequent testing is the best way to contain the virus and ensure that transmission is minimised, especially given the asymptomatic aspect of the disease.

College has already taken steps to ensure that staff and students have access to testing facilities such as the on-site coronavirus testing facilities set to open before the beginning of first term and isolation rooms being provided in Trinitys buildings for staff and students who develop coronavirus symptoms on campus.

David McGrath, director of the College Health Service, told this paper that the testing facilities would as far as possible reduce the development of clusters within the College particularly within student accommodation.

However, these on-campus test facilities will only be used to test students who have displayed symptoms. Students who are asymptomatic could unknowingly be passing on the virus. As McGrath said, students have a responsibility not to infect the public, but they cant take precautions if they dont know whether they are infected.

A Science Foundation Ireland report launched last week revealed that Ireland ranked number one worldwide for immunology research in 2019. With Trinity considered the centre of immunology research in Ireland, College has no shortage of expert advice to consult and take guidance from when it comes to drawing up a testing and containment strategy for campus next year.

Trinity put public safety first when they made the decision to close before other universities when the coronavirus started to take hold in Ireland last March. An on-campus test site and isolation facilities are great first steps in ensuring that campus can reopen safely. However, if College wants to continue to lead the way in university health guidelines, then there needs to be further consideration of testing for all staff and students, not just those with symptoms.

Go here to read the rest:
Trinity is at the Heart of Immunology. It Needs to Take a Lead on Testing - The University Times

Video: COVID-19 Why it Matters, Part 4: Why wash hands/wear mask? – UWGB

This video series features UW-Green Bays Immunologist Brian Merkel on COVID-19 and Why it Matters. This series empowers viewers with knowledge to help them navigate through the pandemic. Merkel has a Ph.D. in Microbiology & Immunology from the Medical College of Virginia. He is an associate professor in UW-Green Bays Human Biology & Biology programs and has an appointment at the Medical College of Wisconsin Department of Microbiology and Immunology. He will be responding to a number of questions related to COVID19 and try to get behind the why its important to be educated in your decision-making as we navigate the pandemic together.

Video Transcript COVID-19 Why it Matters, Part 4: Why wash hands/wear mask?

Brian Merkel, Microbiology and Immunology, talking about Why COVID-19 matters to you.

COVID-19 is a respiratory agent and what that means and why thats important is that it can contaminate surfaces, so we have to be mindful about keeping our hands clean and washing our hands for 20 seconds.

It also means that when we breathe and exhale and when we yell or when we talk and when we cough and we sneeze because this is a respiratory disease, those are all opportunities for the virus to get out in the environment and infect someone else. Given those realities, thats why hand washing becomes very important and its considered to be 20 seconds to be effective. And face coverings very very clearly when both the infected and uninfected when both parties as much face covering and face and mask wearing as we can have the better off were going to be. Because it reduces the ability for the virus to be transmitted and to infect other people.

COVID-19 Why it Matters Video Series:

Visit link:
Video: COVID-19 Why it Matters, Part 4: Why wash hands/wear mask? - UWGB

Sheffield immunologists part of unprecedented national effort to search for answers on Covid-19 – Latest – News – University of Sheffield News

28 August 2020

Three new UK-wide studies will receive 8.4 million from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR) to understand immune responses to the novel coronavirus, SARS-CoV-2.

The largest of these is the UK Coronavirus Immunology Consortium (UK-CIC), which receives 6.5 million in funding. It will bring together scientists at the University of Sheffield with immunologists at 16 other UK universities to investigate the following:

Specifically, the Sheffield team will study two main areas:

The contribution of the University of Sheffield to UK-CIC reflects the notable expertise across the University in both myeloid and T cell biology, and infectious diseases.

Together, it is hoped the studies of the UK-CIC will significantly improve our understanding of this new virus and thus treatment outcomes for patients. They may also inform the development of vaccines and new therapies for Covid-19.

The project will use samples and data from major UK Covid-19 projects already underway, and funded by UKRI and NIHR, including ISARIC-4C (characterising and following more than 75,000 hospitalised patients with Covid-19) and the genomic studies COG-UK (sequencing the SARS-CoV-2 virus genomes) and GenOMICC (sequencing the genomes of people with Covid-19).

The Sheffield team is led by Professor Claire Lewis from the Department of Oncology and Metabolism and Professor Sarah Rowland-Jones, Dr Thushan de Silva and Professor Endre Kiss-Toth from the Department of Infection, Immunity and Cardiovascular Disease.

Claire Lewis, Professor of Molecular and Cellular Pathology at the University of Sheffield, said: We are delighted to be able to contribute to this exciting new immunology consortium. Pooling our expertise and resources in this way will accelerate our understanding of how this coronavirus affects the immune system, and thus how we can defeat it.

The University of Sheffield has a rich heritage of pioneering research to fight infectious disease. In 1941 Sir Howard Florey, former Chair of Pathology at the University of Sheffield, conducted the first ever clinical trials of penicillin a drug which would go on to save more than 82 million lives worldwide.

Pooling our expertise and resources in this way will accelerate our understanding of how this coronavirus affects the immune system, and thus how we can defeat it

Professor Claire Lewis, University of sheffield

Dr Thushan de Silva, Senior Clinical Lecturer in Infectious Diseases at the University of Sheffield, said: We are excited to be working with colleagues across the consortium to characterise the nature and durability of immunity after Covid-19. This work will be key to understanding what immune responses are important in protecting people from re-infection as we move into the next phases of the pandemic.

The UK-CIC consortium is led nationally by Professor Paul Moss at the University of Birmingham, who said: The UK is a world leader in immunology research and its an honour to lead this consortium to deliver a coordinated and agile national research programme to build our knowledge of this disease, which will translate into meaningful benefits for patients. There is so much that we still need to learn about how the novel coronavirus interacts with our immune systems and, with this investment, we have a unique opportunity to answer these key questions and hasten effective pandemic control.

The Humoral Immune Correlates of Covid-19 (HICC) consortium will receive 1.5 million to study the humoral immune response molecules produced by the immune system to fight infection, including antibodies. They will focus on two groups: NHS workers in collaboration with SIREN to track immunity over 12 months, and hospitalised patients.

Both the UK-CIC and HICC have been given urgent public health research status by the Department of Health and Social Care to prioritise their delivery by the health and care system.

The third study will specifically focus on the key features of fatal Covid-19 and the impact the virus has upon the lungs and other vital organs. The project, titled Inflammation in Covid-19: Exploration of Critical Aspects of Pathogenesis, or ICECAP, will receive 394,000.

Chief Medical Officer for England and Head of the NIHR, Professor Chris Whitty, said: Understanding how our immune systems respond to Covid-19 is key to solving some of the important questions about this new disease, including whether those who have had the disease develop immunity and how long this lasts, and why some are more severely affected.

This investment by the NIHR and UKRI will help immunology experts to discover how our immune systems respond to SARS-CoV-2, including our T cell response. This is vital information to help prevent and treat the disease.

These studies build on the UKs world-class expertise and capability in global health and infectious disease that has already shaped our understanding of the pandemic and is informing measures to tackle it.

The full list of research institutions include the University of Birmingham, University of Bristol, University of Cambridge and Wellcome Sanger Institute, UCL, Kings College London, Imperial College London, University of Liverpool, University of Manchester, Newcastle University, University of Oxford, University of Sheffield, University of York, Cardiff University, University of Dundee, University of Edinburgh, University of Glasgow and the Bradford Institute for Health Research.

The University of Sheffield

With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the worlds leading universities.

A member of the UKs prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.

Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.

Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2018 and for the last eight years has been ranked in the top five UK universities for Student Satisfaction by Times Higher Education.

Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields. Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.

UK Research and Innovation works in partnership with universities, research organisations, businesses, charities, and government to create the best possible environment for research and innovation to flourish. We aim to maximise the contribution of each of our component parts, working individually and collectively. We work with our many partners to benefit everyone through knowledge, talent and ideas.

For further information please contact:

Amy HuxtableMedia Relations OfficerThe University of Sheffield0114 222 9859a.l.huxtable@sheffield.ac.uk

Go here to see the original:
Sheffield immunologists part of unprecedented national effort to search for answers on Covid-19 - Latest - News - University of Sheffield News

Cancer Immunology And Oncolytic Virology Market Investigation Highlights Growth Trends in COVID-19 the Coming Years – Kentucky Journal 24

The global cancer immunotherapy market should reach $96.5 billion by 2021 from $73.0 billion in 2016 at a compound annual growth rate (CAGR) of 5.7%, from 2016 to 2021.

Report Scope:

The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies. This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/11805

Report Includes:

An overview of the global markets for cancer immunotherapies and oncolytic virology. Analyses of global market trends, with data from 2015, 2016, and projections of compound annual growth rates (CAGRs) through 2021. Analyses of factors influencing market demand, such as clinical guidelines, demographic changes, and market saturation. Information covering the latest trends, market structure, market size, key drug segments, and trends in technology. Coverage of colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines, and other cancer treatment immunology products. Technological discussions, including the current state, newly issued patents, and pending applications. Profiles of leading companies in the industry.

Report Summary

Cancer is a disease with global implications. There are many different types of cancer, of which the most common types include lung, breast, colon and rectal, stomach, head and neck, prostate, cervical, melanoma, and ovarian cancer, as well as leukemia. Cancer is a genetic disease that is conventionally treated by surgery, radiation therapy, chemotherapy, hormonal therapy, and immunotherapy. Surgery is the mainstay treatment for all cancers. Usually surgery is complimented with radiation or chemotherapy to ensure the clearance of all residual cancer. Despite the advances in treatment, cancer has great plasticity; therefore, after a certain time the effects of treatment fade and cancer returns with acquired resistance. Combination therapy, using multiple modalities including surgery and pharmaceutical or radiation therapy, improves response to treatment.

Radiation and chemotherapy have many side effects. Biological treatment options provide less impactful treatment of cancer. Immunotherapy is a type of biological therapy and it incorporates elements of the immune system in cancer treatment. The immune system has various types of cells and proteins that detect and act upon signs of a disease or infection by harmful and foreign substances such as microbes, bacteria and viruses. The immune system differentiates the bodys own cells and tissues through an evolutionary bar-coding system. This system helps the immune system understand encountered foreign substances as nonself. Cancer cells are recognized as nonself as well. The immune system monitors the body for cancer and destroys when it detects a malignancy. Cancer cells can avoid being recognized by the immune system and develop resistance through numerous methods.

Since the early 1900s, the connection between cancer and the immune system has caught the attention of various scientists and medical practitioners. Although the early studies were bluntly done without current technological and scientific tools, they nonetheless shed insights leading to the development of the first monoclonal antibodies and to the use of biologically derived synthetic interleukins and interferons. After many decades of research, immunotherapy finally emerged as a fully functionalclinical area in the 1990s. Since then, the cancer therapeutics landscape has changed dramatically.

With the stream of product approvals in recent years, the global immunotherapy market has reached its current value. In 2015, the global cancer immunotherapy market hit $65 billion. The current immunotherapy market contains several blockbuster products reaching their end-of-market exclusivities; however, the market is mostly comprised of newly introduced and expensive therapies. In 2016, the market expanded by more than 10% over the previous year, reaching $73 billion. During the period of 2016 through 2021, the global cancer immunotherapy market is forecast to grow by a 5.7% compound annual growth rate (CAGR), reaching $96.5 billion in 2021.

The strongest growth is expected to occur in checkpoint-inhibitor drugs with a 19.4% CAGR during the forecast period. Immunomodulators are anticipated to show the second-highest growth rates among immunotherapy products, with an 8.4% CAGR during the same period. The combined sales from both segments are expected to make up for nearly one-third of the market, with a combined sales value of $28 billion in 2021. Checkpoint inhibitors are virtually comprised of monoclonal antibodies; however,they are assessed separately due to their immense commercial and clinical significance. Sales from other therapeutic antibodies accrued to $28 billion in 2016, and this value is expected to remain relatively constant through 2021, due to several patent expiries, pressure from anticipated generic entries, and newly introduced classes of drugs expected by 2021.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/11805

Read more here:
Cancer Immunology And Oncolytic Virology Market Investigation Highlights Growth Trends in COVID-19 the Coming Years - Kentucky Journal 24

What sewage can tell us about the spread of COVID-19 – High Country News

The sewer is the last stop for Bozeman, Montanas waste, but lately, its the first one for Blake Wiedenhefts work. An associate professor of microbiology and immunology at Montana State University, Wiedenheft has joined other virologists, epidemiologists and immunologists as a member of the universitys COVID-19 task force.

Back in March, a colleague mentioned testing wastewater for evidence of COVID-19 in human waste. The next day, Wiedenheft drove down to Bozemans wastewater treatment plant to see if he could grab a sample. Given how few cases there were in the area at the time, and that 6 million gallons of water flow through the plant daily, he wasnt sure if the virus would be detectable. But Wiedenheft immediately found evidence of it and it kept appearing in the four samples he analyzed over the next 10 days. Wiedenheft worked with local officials to continue regular testing as Bozeman became one of the first cities in the world to look to sewage for answers. Now, cities across the Western United States are sampling wastewater for evidence of SARS-CoV-2 as a potential early warning system for outbreaks. Scientists estimate that up to45% of people infected with the virus show no symptoms. Given that asymptomatic people are less likely to get tested, many cases may go undetected. With many areas experiencing substantial delays in swab test results, daily wastewater testing can give scientists an idea of community infection nearly immediately, Wiedenheft said.

City of Bozeman Wastewater Pre-treatment Coordinator Mark DeWald, left, and Water Reclamation Facility Lab Foreman Josh French, right, separate the housing unit of an autosampler to collect a wastewater sample jug from a Montana State University sewage line collection site.

The autosampler looks like two mini fridges stacked vertically. The top compartment houses a tube and pump, which hoovers up half-cup samples and deposits them into a plastic jug in the cool bottom compartment. Every 24 hours, a sample from this jug is taken to Wiedenhefts lab for testing. Wiedenhefts lab employs the same methods used to analyze COVID-19 nose swab tests: Researchers take RNA whether floating in a liter of wastewater or smeared on a swab and perform a procedure that amplifies the genetic signature of the SARS-CoV-2 virus. That allows researchers to identify the virus.

The challenge of analyzing wastewater, as opposed to a swab, is that RNA samples are such a tiny part of the overall jug of wastewater. Imagine youve got a jar full of jelly beans, and youre dipping into the jar to see if you can find a red jelly bean, said Wiedenheft. If your jar is small, its more likely youre going to scoop up that red jelly bean, but if your jar is big, its less likely, and youre going to have to collect more of the sample to find it. The virus is like the red jelly bean; to get an accurate glimpse into how much virus is in a citys water, scientists have to make sure the samples they collect are representative of its overall water flow. That means taking more frequent samples at peak times in the mornings, when people are starting their routines, or in the evenings, when they are doing chores as well as less frequent samples when the water flow is lower, as it is very early in the morning. Bozemans autosampler collects around three dozen samples daily.

Blake Wiedenheft, associate professor of microbiology and immunology at Montana State University and a member of the universitys COVID-19 task force. Wiedenheft has been working with the City of Bozeman Water Reclamation Facility to monitor the virus.

The upshot of Wiedenhefts lab analyses whether samples are virus positive or negative are posted on the countys public health website. In the 26 samples taken between June and mid-August, the coronavirus was detected every time.

French said they are now experimenting with sampling from specific areas of town, like the hospital and Montana States campus. Engineers have identified their main sewer flow lines and placed mobile samplers just beneath manhole covers, where they collect samples one day a week. As the school year kicks off, MSUs data could track viral spread on campus, while the hospital data could help scientists better understand how their results map on to community spread. We know how much viral protein (Wiedenheft) is detecting in his lab, but how many individuals is that reflective of? asked French.

Researchers have yet to arrive at a definitive answer. Converting wastewater data into an estimate of positive cases requires a key metric scientists are still learning about: how much virus a sick person sheds. That depends on the stage of illness the person is in, as well as how severe the illness is. Because those variables are hard to nail down, Wiedenheft has intentionally avoided reporting such estimates. We dont feel confident enough to make that translation, he said.

But in some cities, officials have released estimates using wastewater data to indicate how many community members are infected. For instance, analyses by Biobot, a wastewater testing startup, estimated that levels of SARS-CoV-2 found in Moscow, Idahos sewage corresponded to 1,800 cases. At the time of the estimate, Latah County, where Moscow is located, had only 46 known cases. (Biobot declined to be interviewed, and its hired communications firm did not answer questions about how the company calculates case estimates. A recent study published by Biobots co-founders and colleagues reported that assumptions about individuals viral load can massively affect these estimates. According to their calculations, assuming infected people have a low viral load leads to an estimate that 5% of the population is infected, whereas assuming a high viral load will lower that estimate to 0.1%.)

It was somewhat reassuring to have another backstop indicator of what was happening.

So far, many local officials have looked to wastewater analyses more as a way to corroborate their knowledge about community viral spread than as a way to estimate case numbers. We wont know how many people in the community have COVID-19 from the methodology, but this data will tell us if trends are going up or down, says Nicole Rowan, clean water program manager at the Colorado Department of Public Health and Environment, which has launched a state-wide wastewater testing effort.

Matt Kelley, health officer at the Gallatin City-County Health Department, said that when his county went through a period of few cases in May, the sewage data gave additional confirmation that spread had slowed. It was somewhat reassuring to have another backstop indicator of what was happening, he said and when positive COVID-19 swab tests rose again, so did levels of SARS-CoV-2 in the water. Kelley said that once cases fall again, it will be helpful to track wastewater as an indicator of undetected community spread. If were not seeing tests in the traditional medical testing, and also not seeing them in the wastewater, thats a validating factor for us.

Ardem Nemudryi, a postdoctoral researcher at Montana State University, uses a bottle top filter to separate SARS-CoV-2 virus RNA from a waste water sample.

As more areas launch wastewater tracking programs, Wiedenheft said theres still one thing needed: a central repository for this data, which could provide a bigger-picture view of viral spread. Over the last few months, Montana has developed several monitoring sites, and some states, like California, Colorado and Wyoming, created their own networks. Its difficult just to compile a list of cities conducting testing, since some key data is private; Biobot said it is working with 400 facilities, but declined to provide additional information, including how many cities that corresponds to. Wiedenheft points to Johns Hopkins popular coronavirus tracker as an example of a well-organized health surveillance tool. It would be nice to have a wastewater surveillance website that does the same thing, where you could look at a geographic map and look at whats happening, he said.

Stay up to date on the West with our free newsletter

Thank you for signing up for our Newsletter.

In mid-August, the U.S. Centers for Disease Control and Department of Health and Human Services announced plans for a National Wastewater Surveillance System, a portal to which health departments can submit their wastewater data. After the federal governments changes to a portal tracking hospital data lead to widespread reporting delays and data inconsistencies, its unclear how the database will fare and whether this new initiative provides funding to areas conducting testing. Wiedenhefts funding goes through August, and hes unsure where the money will come from after that. If wastewater sampling is important and I think it is, since theres plenty of evidence to suggest its really the only real-time indicator in the community then it seems important to have funding to support this ongoing effort, he said. Thats imperative to be able to manage a pandemic.

Note: The section of this story on assumptions about how viral loads impact estimates of community spread has been updated to reflect that assuming a low viral load would mean 5% of the population hasSARS-CoV-2 and that a high viral load could mean as little as 0.1% are infected.

Jane C. Hu is a contributing editor for High Country News and an independent journalist who writes about science, technology and the outdoors. She lives in Seattle. Email her at [emailprotected]or submit a letter to the editor.

Read more:
What sewage can tell us about the spread of COVID-19 - High Country News